[1. Rowe S.M., Miller S., Sorscher E.J. - Cystic fibrosis. N Engl J Med., 2005;352(19):1992-2001.]Search in Google Scholar
[2. Cystic Fibrosis Foundation Patient Registry 2011 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2012.]Search in Google Scholar
[3. Oomen K.P., April M.M. - Sinonasal manifestations in Cystic fibrosis. Int J Otolaryngol., 2012;2012:789572. doi: 10.1155/2012/789572. Epub 2012 Aug 5.10.1155/2012/789572]Search in Google Scholar
[4. Brihaye P., Jorissen M., Clement P.A. - Chronic rinosinusistis in cystic fibrosis (mucoviscidosis). Acta Otorhinolaryngol Belg., 1997;51(4):323-337.]Search in Google Scholar
[5. Steinke J.W., Payne S.C., Chen P.G., Negri J., Stelow E.B., Borish L. - Etiology of nasal polyps in cystic fiborisis: not a unimodal disease. Ann Otol Rhinol Laryngol., 2012;121(9):579-586.]Search in Google Scholar
[6. Tabor A., Alfirevic Z. - Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther., 2010;27(1):1–7. doi: 10.1159/000271995. Epub 2009 Dec 24.10.1159/000271995]Search in Google Scholar
[7. Gentile V.G., Isaacson G. - Patterns of sinusitis in cystic fibrosis. Laryngoscope, 1996;106(8):1005-1009.10.1097/00005537-199608000-00018]Search in Google Scholar
[8. Shapiro E.D., Milmoe G.J., Wald E.R., Rodnan J.B., Bowen A.D. - Bacteriology of the maxillary sinuses in patients with cystic fibrosis. J Infect Dis., 1982;146(5):589–593.]Search in Google Scholar
[9. Halvorson D.J., Dupree J.R., Porubsky E.S. - Management of chronic sinusitis in the adult cystic fibrosis patient. Ann Otol Rhinol Laryngol., 1998;107(11 Pt 1):946–952.10.1177/000348949810701108]Search in Google Scholar
[10. Mak G.K., Henig N.R. - Sinus disease in cystic fibrosis. Clin Rev Allergy Immunol., 2001;21(1):51–63.]Search in Google Scholar
[11. Moss R.B., King V.V. - Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Arch Otolaryngol Head Neck Surg., 1995;121(5):566–572.]Search in Google Scholar
[12. Godoy J.M., Godoy A.N., Ribalta G., Largo I. - Bacterial pattern in chronic sinusitis and cystic fibrosis. Otolaryngol Head Neck Surg., 2011;145(4):673–676. doi: 10.1177/0194599811407279. Epub 2011 Apr 26.10.1177/0194599811407279]Search in Google Scholar
[13. Robertson J.M., Friedman E.M., Rubin B.K. - Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev., 2008;9(3):213–219. doi: 10.1019/j.prrv.2008.04.003. Epub 2008 Jul 31.]Search in Google Scholar
[14. Van Zele T., Claeys S., Gevaert P., Van Maele G., Holtappels G., Van Cauwenberger P., Bachert C. - Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy, 2006;61(11):1280–1289.10.1111/j.1398-9995.2006.01225.x]Search in Google Scholar
[15. Welsh M.J., Smith A.E. - Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell, 1993;73(7):1251–1254.10.1016/0092-8674(93)90353-R]Search in Google Scholar
[16. Accurso F.J., Rowe S.M., Clancy J.P., et al. - Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med., 2010;363(21):1991–2003. doi: 10.1056/NEJmoa0909825.10.1056/NEJMoa0909825]Search in Google Scholar
[17. Gan K.H., Veeze H.J., van den Ouweland A., et al. - A cystic fibrosis mutation associated with mild lung disease. N Engl J Med., 1995;333:95–99.]Search in Google Scholar
[18. Haardt M., Benharouga M., Lechardeur D., Kartner N., Lukacs G.L. - C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem., 1999;274(31):21873–21877.]Search in Google Scholar
[19. Woodworth B.A., Ahn C., Flume P.A., Schlosser R.J. - The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol., 2007;21(1):122–127.]Search in Google Scholar
[20. Nishioka G.J., Cook P.R., McKinsey J.P., Rodriguez F.J. - Paranasal sinus computed tomography scan findings in patients with cystic fibrosis. Otolayngol Head Neck Surg., 1996:114(3):394-399.10.1016/S0194-5998(96)70208-5]Search in Google Scholar
[21. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., Rosenstein B.J., Smith A.L., Wohl M.E. for the Pulmozyme Study Group - Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med., 1994;331:637–642.]Search in Google Scholar
[22. Quan J.M., Tiddens H.A., Sy J.P., McKenzie S.G., Montgomery M.D., Robinson P.J., Wohl M.E., Konstan M.W., Pulmozyme Early Intervention Trial Study Group - A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr., 2001;139(6):813–820.]Search in Google Scholar
[23. Harms H.K., Matouk E., Tournier G., von der Hardt H., Weller P.H., Romano L., Heijerman H.G., FitzGerald M.X., Richard D., Strandvik B., Kolbe J., Kraemer R., Michalsen H. - Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group. Pediatr Pulmonol., 1998;26(3):155–161.]Search in Google Scholar
[24. Konstan M.W., Schluchter M.D., Xue W., Davis P.B. - Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med., 2007;176(11):1084–1089.]Search in Google Scholar
[25. Lindstrom D.R., Conley S.F., Splaingard M.L., Gershan W.M. - Ibuprofen therapy and nasal polyposis in cystic fibrosis patients. J Otolaryngol., 2007;36(5):309–314.]Search in Google Scholar
[26. Suzuki H., Shimomura A., Ikeda K., Furukawa M., Oshima T., Takasaka T. - Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope, 1997;107(12 Pt 1):1661–1666.10.1097/00005537-199712000-000169396683]Search in Google Scholar
[27. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbell P.W. 3rd; Macrolide Study Group. - Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA, 2003;290(13):1749–1756.10.1001/jama.290.13.174914519709]Search in Google Scholar
[28. Lim M., Citardi M.J., Leong J.L. - Topical antimicrobials in the management of chronic rhinosinusitis: a systematic review. Am J Rhinol., 2008;22(4):381–389.]Search in Google Scholar
[29. Kim Chiaw P., Eckford P.D., Bear C.E. - Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem., 2011;50(1):233–248. doi: 10.1042/bse0500233.10.1042/bse050023321967060]Search in Google Scholar
[30. Pettit R.S. - Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother., 2012;46(7-8):1065–1075. doi: 10.1345/aph.1R076. Epub 2012 Jun 26.10.1345/aph.1R07622739718]Search in Google Scholar
[31. Lewiston N., King V., Umetsu D., Starnes V., Marshall S., Kramer M., Theodore J. - Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage. Transplant Proc., 1991;23(1 Pt 2):1207–1208.]Search in Google Scholar
[32. Rowe-Jones J.M., Mackay I.S. - Endoscopic sinus surgery in the treatment of cystic fibrosis with nasal polyposis. Laryngoscope, 1996;106(12 Pt 1):1540–1544.10.1097/00005537-199612000-000198948619]Search in Google Scholar